Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
TERN Stock Forecast 2026-2027
$46.52
Current Price
$5.06B
Market Cap
Buy 11
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to TERN Price Targets
+50.5%
To High Target of $70.00
+22.5%
To Median Target of $57.00
+16.1%
To Low Target of $54.00
TERN Price Momentum
+8.6%
1 Week Change
+23.1%
1 Month Change
+1,362.9%
1 Year Change
+15.1%
Year-to-Date Change
-3.6%
From 52W High of $48.26
+2,394.4%
From 52W Low of $1.87
📊 TOP ANALYST CALLS
Did TERN Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Terns is one of their latest high-conviction picks.
Latest TERN Stock Price Targets & Analyst Predictions
Based on our analysis of 16 Wall Street analysts, TERN has a bullish consensus with a median price target of $57.00 (ranging from $54.00 to $70.00). The overall analyst rating is Strong Buy (9.6/10). Currently trading at $46.52, the median forecast implies a 22.5% upside. This outlook is supported by 11 Buy, 0 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Evan Seigerman at BMO Capital, suggesting a 16.1% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
TERN Analyst Ratings
11
Buy
0
Hold
0
Sell
TERN Price Target Range
Low
$54.00
Average
$57.00
High
$70.00
Current: $46.52
Latest TERN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for TERN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 11, 2025 | Citizens | Silvan Tuerkcan | Market Outperform | Maintains | $57.00 |
| Dec 9, 2025 | HC Wainwright & Co. | Andres Y. Maldonado | Buy | Maintains | $60.00 |
| Dec 9, 2025 | BMO Capital | Evan Seigerman | Outperform | Maintains | $54.00 |
| Dec 9, 2025 | Barclays | Etzer Darout | Overweight | Maintains | $56.00 |
| Dec 9, 2025 | Truist Securities | Srikripa Devarakonda | Buy | Maintains | $56.00 |
| Dec 9, 2025 | Mizuho | Graig Suvannavejh | Outperform | Maintains | $54.00 |
| Dec 9, 2025 | Oppenheimer | Jay Olson | Outperform | Maintains | $58.00 |
| Nov 26, 2025 | Citizens | Silvan Tuerkcan | Market Outperform | Maintains | $35.00 |
| Nov 25, 2025 | Barclays | Etzer Darout | Overweight | Maintains | $36.00 |
| Nov 19, 2025 | Truist Securities | Srikripa Devarakonda | Buy | Maintains | $35.00 |
| Nov 18, 2025 | BMO Capital | Evan Seigerman | Outperform | Maintains | $30.00 |
| Nov 13, 2025 | Mizuho | Graig Suvannavejh | Outperform | Maintains | $33.00 |
| Nov 11, 2025 | Barclays | Etzer Darout | Overweight | Maintains | $28.00 |
| Nov 4, 2025 | Barclays | Etzer Darout | Overweight | Maintains | $27.00 |
| Nov 4, 2025 | Truist Securities | Srikripa Devarakonda | Buy | Reiterates | $28.00 |
| Nov 4, 2025 | HC Wainwright & Co. | Andres Y. Maldonado | Buy | Upgrade | $20.00 |
| Nov 4, 2025 | Mizuho | Graig Suvannavejh | Outperform | Maintains | $32.00 |
| Nov 4, 2025 | BMO Capital | Evan Seigerman | Outperform | Maintains | $22.00 |
| Nov 3, 2025 | Jefferies | Akash Tewari | Buy | Maintains | $35.00 |
| Nov 3, 2025 | William Blair | Andy Hsieh | Outperform | Upgrade | $N/A |
Terns Pharmaceuticals, Inc. (TERN) Competitors
The following stocks are similar to Terns based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
TERN
Terns Pharmaceuticals
mkt cap
5.06B
Terns Pharmaceuticals, Inc. (TERN) Financial Data
Terns Pharmaceuticals, Inc. has a market capitalization of $5.06B with a P/E ratio of -41.5x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -29.1%.
Valuation Metrics
Market Cap
$5.06B
Enterprise Value
$3.69B
P/E Ratio
-41.5x
PEG Ratio
11.6x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+7.1%
Current Ratio
19.5x
Debt/Equity
0.4x
ROE
-29.1%
ROA
-19.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Terns Pharmaceuticals, Inc. (TERN) Business Model
About Terns Pharmaceuticals, Inc.
What They Do
Develops therapies for liver disease and oncology.
Business Model
The company focuses on discovering and developing novel therapeutic candidates for liver diseases, particularly non-alcoholic steatohepatitis (NASH), and oncology. It generates revenue through advancing its pipeline of clinical and preclinical drug candidates, addressing significant unmet medical needs.
Additional Information
Terns Pharmaceuticals is actively pursuing innovative mechanisms, such as small molecules to reduce liver inflammation and fibrosis. The company's expansion into oncology demonstrates its commitment to diversifying its treatment options and enhancing its impact within the healthcare industry, potentially transforming chronic disease management.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
59
CEO
Ms. Amy L. Burroughs M.B.A.
Country
United States
IPO Year
2021
Website
www.ternspharma.comTerns Pharmaceuticals, Inc. (TERN) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
4 Biotech Stocks to Watch for Potential Upside in 2026
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position TERN, ADMA, ANIP and LQDA in this volatile sector.
Mar 13, 2026
By Ekta Bagri
Industry Outlook
Latest News
Quick Summary
Boxer Capital added 375,000 shares of TERN, valued at $15.15 million, reflecting a 3.32% increase in its 13F reportable assets. TERN is a new position, not in the top five holdings.
Why It Matters
Boxer Capital's new position in TERN, valued at $15.15 million, indicates confidence in the stock's potential, which could influence market perceptions and trading dynamics.
Source: The Motley Fool
Market Sentiment:
Positive
Quick Summary
Terns Pharmaceuticals (Nasdaq: TERN) will have senior management participating in investor conferences in March 2026, focusing on its clinical-stage oncology developments.
Why It Matters
Terns Pharmaceuticals' participation in investor conferences may signal potential developments or partnerships, influencing market perception and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
ORBIMED Advisors Trims $125 Million Terns Stake After a Breakout Year, According to SEC Filing
23 days ago
Quick Summary
ORBIMED Advisors reduced its stake in Terns Pharmaceuticals by 5.4 million shares, valuing the trade at $125.01 million. The position is now 2.15 million shares, worth $87 million, and represents 1.78% of AUM.
Why It Matters
ORBIMED's reduction in Terns Pharmaceuticals stake signals a loss of confidence, potentially affecting stock performance and influencing other investors' decisions.
Source: The Motley Fool
Market Sentiment:
Neutral
Quick Summary
First Turn Management acquired 872,049 shares of Terns Pharmaceuticals in Q4, increasing the position's value by $35.23 million due to new investments and stock price changes.
Why It Matters
The acquisition of shares by First Turn Management indicates confidence in Terns Pharmaceuticals, potentially driving stock price and investor interest higher.
Source: The Motley Fool
Market Sentiment:
Positive
Quick Summary
Terns Pharmaceuticals (TERN) has a consensus price target indicating a 50.9% upside potential. Upward earnings estimate revisions suggest possible near-term stock gains.
Why It Matters
Terns Pharmaceuticals has a price target suggesting significant upside potential. Positive earnings estimate revisions could indicate imminent stock price growth.
Source: Zacks Investment Research
Market Sentiment:
Positive
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
1 month ago
Quick Summary
Terns Pharmaceuticals granted equity inducement awards to two new employees on February 1, 2026, under its amended 2022 Employment Inducement Award Plan.
Why It Matters
Equity inducement awards signal Terns Pharmaceuticals' commitment to attracting talent, which can enhance innovation and growth potential, impacting future performance and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About TERN Stock
What is Terns Pharmaceuticals, Inc.'s (TERN) stock forecast for 2026?
Based on our analysis of 16 Wall Street analysts, Terns Pharmaceuticals, Inc. (TERN) has a median price target of $57.00. The highest price target is $70.00 and the lowest is $54.00.
Is TERN stock a good investment in 2026?
According to current analyst ratings, TERN has 11 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $46.52. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for TERN stock?
Wall Street analysts predict TERN stock could reach $57.00 in the next 12 months. This represents a 22.5% increase from the current price of $46.52. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Terns Pharmaceuticals, Inc.'s business model?
The company focuses on discovering and developing novel therapeutic candidates for liver diseases, particularly non-alcoholic steatohepatitis (NASH), and oncology. It generates revenue through advancing its pipeline of clinical and preclinical drug candidates, addressing significant unmet medical needs.
What is the highest forecasted price for TERN Terns Pharmaceuticals, Inc.?
The highest price target for TERN is $70.00 from at , which represents a 50.5% increase from the current price of $46.52.
What is the lowest forecasted price for TERN Terns Pharmaceuticals, Inc.?
The lowest price target for TERN is $54.00 from Evan Seigerman at BMO Capital, which represents a 16.1% increase from the current price of $46.52.
What is the overall TERN consensus from analysts for Terns Pharmaceuticals, Inc.?
The overall analyst consensus for TERN is bullish. Out of 16 Wall Street analysts, 11 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $57.00.
How accurate are TERN stock price projections?
Stock price projections, including those for Terns Pharmaceuticals, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: March 15, 2026 4:54 PM UTC